Atara Biotherapeutics Torn by Regulatory Feedback on EBVALLO
Atara Biotherapeutics, Inc. (NASDAQ: ATRA), an innovator in T-cell immunotherapy, has provided a notable update on EBVALLO™ (tabelecleucel), a pioneering therapy targeting Epstein-Barr virus (EBV) related diseases. Recently, the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning the Biologics License Application (BLA) for EBVALLO, specifically for its use in adult and pediatric patients diagnosed with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Understanding the Complete Response Letter
The CRL is not an outright disapproval but is a reflection of findings during a routine pre-licensure inspection at a third-party manufacturing facility assigned to produce EBVALLO. Importantly, the FDA did not raise any concerns regarding the clinical efficacy or safety data associated with this therapy. This means that, while the manufacturing pathway needs refinement, the pivotal clinical data supporting EBVALLO's usage remains robust.
Collaboration and Future Steps
In a statement, Cokey Nguyen, Ph.D., President and CEO of Atara Biotherapeutics, highlighted a commitment to working closely with Pierre Fabre Laboratories, the FDA, and the manufacturing partner to resolve any indicated compliance issues. Dr. Nguyen expressed optimism that a successful resubmission could lead to approval within six months, reinforcing Atara's commitment to delivering this promising treatment to patients afflicted by EBV+ PTLD.
Eric Ducournau, CEO of Pierre Fabre Laboratories, echoed the urgency of bringing EBVALLO to patients struggling with this rare disease, emphasizing the critical nature of the work ahead.
Market Potential and Regulatory Progress
EBVALLO is an allogeneic T-cell immunotherapy that has already gained marketing authorization from the European Commission, highlighting its international acceptance. The promising data from the pivotal ALLELE trial, which showed a striking 50% Objective Response Rate (ORR), augments the hope surrounding its pending approval in the U.S.
Furthermore, Atara recently noted an additional manufacturing facility by FUJIFILM Diosynth Biotechnologies (FDB) has been approved by the EMA, which will support the global manufacturing strategy for EBVALLO going forward. This access to another reputable manufacturer is crucial in bolstering the overall supply chain for the product.
Strategic Alternatives and Financial Resilience
In light of its broader operational strategies, Atara's Board has been actively reviewing various strategic alternatives that may enhance its market position. These discussions encompass possibilities like acquisitions, mergers, and other business combinations that can maximize shareholder value. Atara is also exploring various financing options, including a recent non-binding agreement with Redmile Group aiming to provide up to $15 million in funding through an equity line of credit, which is expected to be enough to sustain the necessary activities for securing BLA approval.
Commitment to Shareholders and Future Directions
Atara is committed to maintaining transparency with its shareholders regarding potential milestone payments and royalties from Pierre Fabre associated with the commercialization of EBVALLO. These financial avenues, including a notable $60 million milestone payment upon FDA approval, are designed to strengthen Atara's financial foundation and align with the company’s goal of advancing innovative treatments from the lab to patients.
Should there be challenges in securing suitable funding for ongoing CAR-T program developments by early in the year following the fiscal close, Atara plans to streamline its operations predominantly towards the approval of EBVALLO. This strategic pivot ensures that vital resources maintain focus on the potential of this breakthrough therapy.
About Atara Biotherapeutics
Atara Biotherapeutics is dedicated to leveraging immune system mechanisms to develop advanced therapies aimed at complicated cancers and autoimmune diseases. The company is recognized for its pioneering work in allogeneic T-cell immunotherapy, providing solutions that do not require extensive customization. There is a strong focus on treating diseases driven by EBV and creating next-generation AlloCAR-T therapies poised to make a significant impact in a variety of hematological cancers.
Frequently Asked Questions
What is EBVALLO?
EBVALLO is a T-cell immunotherapy designed to treat patients with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
What did the FDA communicate in the Complete Response Letter?
The FDA's CRL was related to issues found during a standard pre-licensure inspection of a third-party manufacturing facility, without indicating any efficacy or safety data concerns.
How is Atara Biotherapeutics addressing the findings?
Atara is collaborating with Pierre Fabre Laboratories and the third-party manufacturer to address compliance issues and aims to resubmit the BLA once resolved.
What are the financial implications of EBVALLO's approval?
Atara is positioned to receive substantial milestone payments and tiered royalties upon the successful commercialization of EBVALLO.
What is the company's current financial strategy?
Atara is exploring various financing options and has entered into a non-binding agreement to secure additional capital to support its operations.
